MX2023001145A - Suppression of cytokine release and cytokine storm. - Google Patents
Suppression of cytokine release and cytokine storm.Info
- Publication number
- MX2023001145A MX2023001145A MX2023001145A MX2023001145A MX2023001145A MX 2023001145 A MX2023001145 A MX 2023001145A MX 2023001145 A MX2023001145 A MX 2023001145A MX 2023001145 A MX2023001145 A MX 2023001145A MX 2023001145 A MX2023001145 A MX 2023001145A
- Authority
- MX
- Mexico
- Prior art keywords
- cytokines
- cytokine
- curcumin
- release
- trigger
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 title abstract 4
- 108090000695 Cytokines Proteins 0.000 title abstract 4
- 206010050685 Cytokine storm Diseases 0.000 title 1
- 206010052015 cytokine release syndrome Diseases 0.000 title 1
- 230000001629 suppression Effects 0.000 title 1
- 208000035473 Communicable disease Diseases 0.000 abstract 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 2
- 229940109262 curcumin Drugs 0.000 abstract 2
- 239000004148 curcumin Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 239000012736 aqueous medium Substances 0.000 abstract 1
- 235000012754 curcumin Nutrition 0.000 abstract 1
- 235000020241 curcumin extract Nutrition 0.000 abstract 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001960 triggered effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medical Informatics (AREA)
- Toxicology (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
Abstract
The present invention includes methods and compositions for ameliorating symptoms or treating one or more adverse reactions triggered by infectious diseases or disease conditions that trigger a widespread release of cytokines in a subject comprising the steps of: identifying the subject in need of amelioration of symptoms or treatment of the infectious diseases or disease conditions that trigger a widespread release of cytokines; and administering one or more pharmaceutical compositions comprising a therapeutically effective amount of a curcumin extract, curcuminoids or synthetic curcumin (S-curcumin) and derivatives thereof, and lipids dissolved or dispersed in a suitable aqueous or non-aqueous medium sufficient to reduce the level of cytokines in the host.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/945,195 US20200360300A1 (en) | 2014-12-31 | 2020-07-31 | Suppression of Cytokine Release and Cytokine Storm |
| PCT/US2021/041403 WO2022026170A1 (en) | 2020-07-31 | 2021-07-13 | Suppression of cytokine release and cytokine storm |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001145A true MX2023001145A (en) | 2023-03-06 |
Family
ID=80036956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001145A MX2023001145A (en) | 2020-07-31 | 2021-07-13 | Suppression of cytokine release and cytokine storm. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4188398A1 (en) |
| JP (1) | JP2023536833A (en) |
| KR (1) | KR20230026468A (en) |
| CN (1) | CN116710123A (en) |
| AU (1) | AU2021315452A1 (en) |
| CA (1) | CA3189374A1 (en) |
| MX (1) | MX2023001145A (en) |
| TW (1) | TW202207907A (en) |
| WO (1) | WO2022026170A1 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104602672B (en) * | 2012-06-14 | 2018-12-25 | 伯尔尼大学 | For treating the customization liposome of bacterium infection |
| US10286065B2 (en) * | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
| US20200360300A1 (en) * | 2014-12-31 | 2020-11-19 | Signpath Pharma, Inc. | Suppression of Cytokine Release and Cytokine Storm |
| US10739353B2 (en) * | 2014-12-31 | 2020-08-11 | Signpath Pharma, Inc. | Suppression of cytokine release and cytokine storm |
| EP3405587A4 (en) * | 2015-12-23 | 2019-10-30 | Moonshot Pharma LLC | Methods for inducing an immune response by promoting premature termination codon read-through |
-
2021
- 2021-07-13 JP JP2023505892A patent/JP2023536833A/en active Pending
- 2021-07-13 MX MX2023001145A patent/MX2023001145A/en unknown
- 2021-07-13 EP EP21850964.4A patent/EP4188398A1/en active Pending
- 2021-07-13 AU AU2021315452A patent/AU2021315452A1/en active Pending
- 2021-07-13 TW TW110125635A patent/TW202207907A/en unknown
- 2021-07-13 CN CN202180058955.0A patent/CN116710123A/en active Pending
- 2021-07-13 WO PCT/US2021/041403 patent/WO2022026170A1/en active Application Filing
- 2021-07-13 KR KR1020237002192A patent/KR20230026468A/en active Search and Examination
- 2021-07-13 CA CA3189374A patent/CA3189374A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3189374A1 (en) | 2022-02-03 |
| TW202207907A (en) | 2022-03-01 |
| JP2023536833A (en) | 2023-08-30 |
| WO2022026170A1 (en) | 2022-02-03 |
| KR20230026468A (en) | 2023-02-24 |
| EP4188398A1 (en) | 2023-06-07 |
| AU2021315452A1 (en) | 2023-02-02 |
| CN116710123A (en) | 2023-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abeck et al. | Extragenital cutaneous warts–clinical presentation, diagnosis and treatment | |
| Sgarbanti et al. | Intracellular redox state as target for anti-influenza therapy: are antioxidants always effective? | |
| MX2019004549A (en) | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof. | |
| MX2017010220A (en) | Formulations for oral administration of active agents with controlled absorption profile. | |
| JP6966998B2 (en) | Formulations for the treatment of oral, throat and airway disorders | |
| BR112021026334A2 (en) | HDac6-activated macrophages, compositions, and uses thereof | |
| SI2760821T1 (en) | Choline salt of an anti-inflammatory substituted cyclobutenedione compound | |
| UA117506C2 (en) | Pharmaceutical preparation including pyridylamino acetic acid compound | |
| HRP20211286T1 (en) | Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine | |
| JP2016516801A (en) | Immune micronutrient | |
| AR108829A1 (en) | VACCINE AGAINST INFECTIOUS BRONCHITIS VIRUS | |
| BR112022015313A2 (en) | HPV VACCINE | |
| MX2023001145A (en) | Suppression of cytokine release and cytokine storm. | |
| JP2016512247A5 (en) | ||
| CO6361950A2 (en) | COMPOSITIONS, VACCINES AND METHODS OF THE VIRUS OF HERPES OF BOVINE LIVES -1 | |
| WO2022192594A3 (en) | Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease | |
| BR112018072298A2 (en) | treatment of Zika virus infections using alpha-glucosidase inhibitors | |
| MX2021015576A (en) | Extended release gastroretentive formulation against helicobacter pylori. | |
| RU2017125426A (en) | The use of taurine for the prevention and / or treatment of diseases caused by viruses of the genus coronaviruses and / or the genus rotaviruses | |
| Singh et al. | Antibacterial and anticancer activities of turmeric and its active ingredient curcumin, and mechanism of action | |
| A Marathe et al. | Herbal cocktail as anti-infective: promising therapeutic for the treatment of viral diseases | |
| EP2849735A1 (en) | Vaginal cream for the treatment of papilloma infection comprising docosanol, turmeric, amla and aloe | |
| JP6100510B2 (en) | Anti-cold medicine | |
| MX2022004869A (en) | Chikungunya virus-like particle vaccine and methods of using the same. | |
| MX2023006235A (en) | Compositions for drug delivery and methods of use thereof. |